FluoroPharma Medical (FluoroPharma Medical) COGS-to-Revenue : 0.00 (As of Dec. 2016)

View and export this data going back to 2008. Start your Free Trial

What is FluoroPharma Medical COGS-to-Revenue?

FluoroPharma Medical's Cost of Goods Sold for the three months ended in Dec. 2016 was $0.00 Mil. Its Revenue for the three months ended in Dec. 2016 was $0.00 Mil.

FluoroPharma Medical's COGS to Revenue for the three months ended in Dec. 2016 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. FluoroPharma Medical's Gross Margin % for the three months ended in Dec. 2016 was N/A%.

FluoroPharma Medical COGS-to-Revenue Historical Data

The historical data trend for FluoroPharma Medical's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FluoroPharma Medical COGS-to-Revenue Chart

FluoroPharma Medical Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

COGS-to-Revenue

Get a 7-Day Free Trial

FluoroPharma Medical Quarterly Data
	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

FluoroPharma Medical COGS-to-Revenue Calculation

FluoroPharma Medical's COGS to Revenue for the fiscal year that ended in Dec. 2016 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

FluoroPharma Medical's COGS to Revenue for the quarter that ended in Dec. 2016 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

FluoroPharma Medical (OTCPK:FPMI) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

FluoroPharma Medical's Gross Margin % for the three months ended in Dec. 2016 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

FluoroPharma Medical COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of FluoroPharma Medical's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

FluoroPharma Medical (FluoroPharma Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FluoroPharma Medical Inc (OTCPK:FPMI) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 Hillside Avenue, Suite 108, Montclair, NJ, USA, 07042

Website

http://www.fluoropharma.com

FluoroPharma Medical Inc is a US-based biopharmaceutical company. It specializes in developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents which detect and assess acute and chronic forms of coronary artery disease (CAD). The company's clinical-stage molecular imaging pharmaceutical product candidates are 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). The 18-F TPP is designed for use in stress-testing for patients with proven CAD whereas 18-F FCPHA is a molecular imaging agent which is designed to assess myocardial blood flow and metabolism in patients with CAD. The company operates in a single segment being Biopharmaceutical research and development.

Executives

Johan M. Spoor

director, officer: CEO, PRESIDENT, CHAIRMAN

500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116

FluoroPharma Medical (FluoroPharma Medical) Headlines

From GuruFocus

FPMI Restructures CardioPET License With Massachusetts General Hospital

By Marketwired Marketwired • 09-27-2018